Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer

Ridho Assidicky(Bilkent University), Özgür Şahin(Medical University of South Carolina)

Breast Cancer Research and Treatment

March 25, 2022

10.1007/s10549-022-06569-5

Cited by 58

Related Papers

Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer

|Oncogene|2012|286

The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer

|Oncotarget|2016|59

A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer

|Cell chemical biology|2024|24